The OptoScannar™ device is a non-invasive, optical monitor that senses THC concentration in blood, eliminating the need for invasive blood extraction. Through a novel technique for illumination and direct absorption in the “optical tissue window”, we minimize the scattering effects of light in tissue achieving high “signal to noise” for detection of specific absorption levels for fast, accurate measurements.
OptoScannar’s target markets are:
· Law enforcement – Requires a portable, field sobriety detector for monitoring THC levels in blood.
· Doctors and hospitals – Administering and monitoring patients using cannabinoid therapy.
· Home medical users – Monitoring various cannabinoid products for best effectiveness.
· Recreational users – Monitoring residual THC levels for legal compliance at work and driving.
The THC sensing technique is non-invasive, accurate, and fast. Users of cannabinoids will now be able to measure total dose levels and monitor their trailing residual levels for managing their dosing regimens. Law enforcement will now have a portable evaluation method to assist in fair and legal field sobriety testing. Our sensing technique can also be tuned to sense other compounds in skin such as CBD and THCV.
Airware’s Direct Infrared Laser Absorptive Scattering Technique (DILAST™) brings the “time” element into play by employing fast alternate and sequential pulses from a signal and a reference narrow-band light source. The signal radiation is preferentially absorbed by the targeted molecules and the reference radiation, which is close in wavelength to that of the signal and has minimal absorption by the targeted molecules in the medium under test. The detector outputs of the fast pulse pairs, which see essentially the same fixed environment, are ratioed and appropriately averaged to generate the concentration of the targeted molecules.
In this optical measurement arrangement, both the signal and reference beams essentially experience the same scattering events differing only in the absorption of the targeted molecule. The effect of deleterious scattering on the measurement is significantly suppressed.
Currently, OptoScannar™ has filed four patents. The company is pre-money and sixteen months from distributing initial devices. Our plan is to work with a contract manufacturer in the U.S. to build, test, calibrate, and package the hardware.
We are aware of potential competition from breathalyzer devices and saliva tests in development. For the time being, a blood test requiring about 7 ml is the most precise measurement of active THC. The OptoScannar™ will potentially become the fast, accurate, non-invasive standard for THC home and law enforcement field testing.